Efficacy of FOLFOX4 as adjuvant therapy in stage II colon cancer (CC): A new analysis of the MOSAIC trial according to risk factors

被引：0
|
作者：
Teixeira, L.
Hickish, T.
Tournigand, C.
Bachet, J.
Bonetti, A.
Rivera, F.
Boni, C.
Tabernero, J.
Andre, T.
De Gramont, A.
机构：
[1] Hop St Antoine, F-75571 Paris, France
[2] Dorset Canc Network, Bournemouth, Dorset, England
[3] Bournemouth Univ, Bournemouth, Dorset, England
[4] Grp Hosp Pitie Salpetriere, F-75634 Paris, France
[5] Dept Med Oncol, Legnago, Italy
[6] Hosp Univ Marques de Valdecilla, Santander, Spain
[7] Arcispedale S Maria Nuova, Reggio Emilia, Italy
[8] Vall dHebron Univ Hosp, Barcelona, Spain
[9] Hop La Pitie Salpetriere, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3524
引用
收藏
页数：2
相关论文
共 50 条
  • [21] New Developments in the Adjuvant Therapy of Stage II Colon Cancer Risk Assessments in the Older Patient
    McCleary, Nadine Jackson
    Meyerhardt, Jeffrey A.
    ONCOLOGY-NEW YORK, 2010, 24 (01): : 3 - 8
  • [22] ADJUVANT FOLFOX4 PLUS OR MINUS CETUXIMAB (CMAB) IN PATIENTS (PTS) WITH KRAS MUTANT (MKRAS) RESECTED STAGE III COLON CANCER (CC). RESULTS FROM THE PETACC8 INTERGROUP TRIAL
    Salazar, R.
    Mini, E.
    Folprecht, G.
    Subtil, F.
    van Laethem, J.
    Thaler, J.
    Bridgewater, J. A.
    Van Cutsem, E.
    Lepage, C.
    Taieb, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 178 - 179
  • [23] Risk Assessment and Adjuvant Systemic Therapy in Resected Stage II Colon Cancer
    Shankaran, Veena
    Khrizman, Polina
    Benson, Al B., III
    CURRENT COLORECTAL CANCER REPORTS, 2009, 5 (03) : 158 - 165
  • [24] Identification of high risk stage II colon cancer patients for adjuvant therapy
    Quah, H.
    Wong, W.
    Shia, J.
    Schrag, D.
    Guillem, J.
    Paty, P.
    Temple, L.
    Weiser, M.
    DISEASES OF THE COLON & RECTUM, 2007, 50 (05) : 710 - 710
  • [25] FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial (vol 36, pg 1478, 2018)
    Sobrero
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (18) : 1893 - 1893
  • [26] Evaluation of the Efficacy of Modified De Gramont and Modified FOLFOX4 Regimens for Adjuvant Therapy of Locally Advanced Rectal Cancer
    Koca, Dogan
    Oztop, Ilhan
    Yavuzsen, Tugba
    Ellidokuz, Hulya
    Yilmaz, Ugur
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2011, 12 (12) : 3181 - 3186
  • [27] Practical Outcome of Adjuvant FOLFOX4 Chemotherapy in Elderly Patients with Stage III Colon Cancer: Single-center Study in Korea
    Kim, Ji-Yeon
    Kim, Yu Jung
    Lee, Keun-Wook
    Lee, Jong Seok
    Kim, Duck-Woo
    Kang, Sung-Bum
    Lee, Hye Seung
    Jang, Na Young
    Kim, Jae-Sung
    Kim, Jee Hyun
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (02) : 132 - 138
  • [28] Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair
    Hu, Huabin
    Wu, Zehua
    Wang, Chao
    Huang, Yan
    Zhang, Jianwei
    Cai, Yue
    Xie, Xiaoyu
    Li, Jianxia
    Shen, Cailu
    Li, Weiwei
    Ling, Jiayu
    Xu, Xuehu
    Deng, Yanhong
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [29] ERBB2 Alterations a New Prognostic Biomarker in Stage III Colon Cancer (CC) from a FOLFOX Based Adjuvant Trial (PETACC8)
    Penult-Llorca, Frederique
    Laurent-Puig, Pierre
    Cayre, Anne
    Le Malicot, Karine
    Emile, Jean-Francois
    Taieb, Julien
    LABORATORY INVESTIGATION, 2017, 97 : 195A - 195A
  • [30] ERBB2 Alterations a New Prognostic Biomarker in Stage Ill Colon Cancer (CC) from a FOLFOX Based Adjuvant Trial (PETACC8)
    Penault-Llorca, Frederique
    Laurent-Puig, Pierre
    Cayre, Anne
    Le Malicot, Karine
    Emile, Jean-Francois
    Taieb, Julien
    MODERN PATHOLOGY, 2017, 30 : 195A - 195A
12345